UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2025 (Report No. 8)
Commission File Number: 001-39957
NLS PHARMACEUTICS LTD.
(Translation of registrant’s name into
English)
The Circle 6
8058 Zurich, Switzerland
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F
☐ Form 40-F
CONTENTS
On October 30, 2025, NLS Pharmaceutics
Ltd. issued a press release titled: “NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs.”
A copy of this press release is furnished herewith as Exhibit 99.1.
EXHIBIT INDEX
Exhibit
Number |
|
Description of Document |
| 99.1 |
|
Press release titled: “NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs” |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
NLS Pharmaceutics Ltd. |
| |
|
|
|
| Date: October 30, 2025 |
By: |
/s/ Alexander C. Zwyer |
| |
|
Name: |
Alexander C. Zwyer |
| |
|
Title: |
Chief Executive Officer |
